Form 4: CG Oncology Director Receives Stock Option Grant

Director Victor Edward Tong Jr. was granted 9,354 stock options in CG Oncology, Inc. as part of a standard equity incentive.

Summary

• Director Victor Edward Tong Jr. received a grant of 9,354 stock options on June 4, 2026.
• The options have an exercise price of $56.09 per share.
• The options are set to expire on June 3, 2036.
• Vesting occurs in 1/12th monthly increments following the grant date, with a provision for full vesting upon the next annual stockholder meeting if it occurs before the first anniversary.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $56.09 exercise price.

Future Outlook

The grant indicates ongoing equity-based compensation for board members, aligning director incentives with the company's long-term performance.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term clinical and commercial success.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard corporate governance practices for mid-cap biotechnology companies.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on a monthly basis starting July 2026.

Key Dates

Keywords

CG Oncology, CGON, Form 4, Insider Trading, Stock Options, Director Compensation